Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: A Tertiary Center Experience
Introduction: The frequency, risk factors, and outcome of Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) infection in patients with inflammatory bowel disease (IBD) remain unclear. This study aimed to investigate the incidence and effects of SARS-CoV-2 infection in IBD. Materials and...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Turkish |
| Published: |
Galenos Yayinevi
2022-08-01
|
| Series: | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| Subjects: | |
| Online Access: | https://mjima.org/abstract.php?id=323 |
| _version_ | 1797908537254346752 |
|---|---|
| author | Batuhan BAŞPINAR İbrahim Ethem GÜVEN İlhami YÜKSEL |
| author_facet | Batuhan BAŞPINAR İbrahim Ethem GÜVEN İlhami YÜKSEL |
| author_sort | Batuhan BAŞPINAR |
| collection | DOAJ |
| description | Introduction: The frequency, risk factors, and outcome of Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) infection in patients with inflammatory bowel disease (IBD) remain unclear. This study aimed to investigate the incidence and effects of SARS-CoV-2 infection in IBD.
Materials and Methods: Patients with IBD were recruited retrospectively between March 2020 and March 2021, and those with SARS-CoV-2 infection were analyzed.
Results: A total of 894 patients with IBD were identified during the study period. SARS-CoV-2 was detected in 18 (2.0%) patients, including five (1.2%) of the 430 patients with Crohn’s disease (CD), 12 (2.8%) of 428 patients with ulcerative colitis (UC) and, one (2.8%) of 36 with unclassified IBD. The mean age was 42.2 years. Twelve (66.7%) of the patients were men. None of the patients was vaccinated for Coronavirus disease-2019. Five (27.8%) patients were hospitalized for a median of 10 days; the remaining patients were isolated at home. No intensive care unit admission or mortality occurred. Although a disease flare was not observed, a patient with UC who was on steroids demonstrated temporary terminal ileitis, pneumonitis intestinalis, and recto-vaginal fistulae. Six (33.3%) patients were on biologic agents, with one having concomitant immunomodulator and steroid therapy. The main gastrointestinal (GI) symptom was diarrhea in six (33.3%) patients.
Conclusion: The incidence of SARS-CoV-2 infection was 2.0% (n=18) in patients with IBD. Diarrhea is the most common GI symptom and should not be confused with IBD flare. |
| first_indexed | 2024-04-10T10:54:24Z |
| format | Article |
| id | doaj.art-787a147d5595421c89571df7eead4bc4 |
| institution | Directory Open Access Journal |
| issn | 2147-673X |
| language | Turkish |
| last_indexed | 2024-04-10T10:54:24Z |
| publishDate | 2022-08-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| spelling | doaj.art-787a147d5595421c89571df7eead4bc42023-02-15T16:20:01ZturGalenos YayineviMediterranean Journal of Infection, Microbes and Antimicrobials2147-673X2022-08-0111110.4274/mjima.galenos.2022.2021.25Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: A Tertiary Center ExperienceBatuhan BAŞPINAR0https://orcid.org/0000-0003-3143-2642İbrahim Ethem GÜVEN1https://orcid.org/0000-0002-7436-6414İlhami YÜKSEL2https://orcid.org/0000-0002-9730-2309Ankara City Hospital, Clinic of Gastroenterology and Hepatology, Ankara, TurkeyAnkara City Hospital, Clinic of Gastroenterology and Hepatology, Ankara, TurkeyAnkara Yıldırım Beyazit University Faculty of Medicine, Department of Gastroenterology, Ankara, TurkeyIntroduction: The frequency, risk factors, and outcome of Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) infection in patients with inflammatory bowel disease (IBD) remain unclear. This study aimed to investigate the incidence and effects of SARS-CoV-2 infection in IBD. Materials and Methods: Patients with IBD were recruited retrospectively between March 2020 and March 2021, and those with SARS-CoV-2 infection were analyzed. Results: A total of 894 patients with IBD were identified during the study period. SARS-CoV-2 was detected in 18 (2.0%) patients, including five (1.2%) of the 430 patients with Crohn’s disease (CD), 12 (2.8%) of 428 patients with ulcerative colitis (UC) and, one (2.8%) of 36 with unclassified IBD. The mean age was 42.2 years. Twelve (66.7%) of the patients were men. None of the patients was vaccinated for Coronavirus disease-2019. Five (27.8%) patients were hospitalized for a median of 10 days; the remaining patients were isolated at home. No intensive care unit admission or mortality occurred. Although a disease flare was not observed, a patient with UC who was on steroids demonstrated temporary terminal ileitis, pneumonitis intestinalis, and recto-vaginal fistulae. Six (33.3%) patients were on biologic agents, with one having concomitant immunomodulator and steroid therapy. The main gastrointestinal (GI) symptom was diarrhea in six (33.3%) patients. Conclusion: The incidence of SARS-CoV-2 infection was 2.0% (n=18) in patients with IBD. Diarrhea is the most common GI symptom and should not be confused with IBD flare.https://mjima.org/abstract.php?id=323covid-19crohn’s diseaseinflammatory bowel diseasessars-cov-2 |
| spellingShingle | Batuhan BAŞPINAR İbrahim Ethem GÜVEN İlhami YÜKSEL Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: A Tertiary Center Experience Mediterranean Journal of Infection, Microbes and Antimicrobials covid-19 crohn’s disease inflammatory bowel diseases sars-cov-2 |
| title | Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: A Tertiary Center Experience |
| title_full | Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: A Tertiary Center Experience |
| title_fullStr | Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: A Tertiary Center Experience |
| title_full_unstemmed | Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: A Tertiary Center Experience |
| title_short | Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: A Tertiary Center Experience |
| title_sort | outcomes of covid 19 in patients with inflammatory bowel disease a tertiary center experience |
| topic | covid-19 crohn’s disease inflammatory bowel diseases sars-cov-2 |
| url | https://mjima.org/abstract.php?id=323 |
| work_keys_str_mv | AT batuhanbaspinar outcomesofcovid19inpatientswithinflammatoryboweldiseaseatertiarycenterexperience AT ibrahimethemguven outcomesofcovid19inpatientswithinflammatoryboweldiseaseatertiarycenterexperience AT ilhamiyuksel outcomesofcovid19inpatientswithinflammatoryboweldiseaseatertiarycenterexperience |